

JOHN A. BRENNAN, MD, MPH
President and Chief Executive Officer
Newark Beth Israel Medical Center
Children's Hospital of New Jersey

BARRY H. OSTROWSKY
President and Chief Executive Officer
Barnabas Health

October 1, 2015

Dear Manufacturers,

I am writing on behalf of Newark Beth Israel Medical Center (NBIMC; 340B ID# DSH310002) to inform manufacturers that NBIMC recently underwent an audit by the Health Resources and Services Administration (HRSA) of NBIMC's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, NBIMC qualified for the 340B Program as a Disproportionate Share Hospital (DSH) located at 201 Lyons Ave, Newark, NJ, 07112 and has participated in the 340B Program since October 1, 2004.

Through the audit process, NBIMC was found to have non-compliance within our 340B Program and responsible for repayment as a result of the following finding(s):

NBIMC dispensed 340B drugs to ineligible individuals, as prohibited by 42 USC256b(a)(5)(B).

NBIMC has identified all affected manufacturers and is in the process of repayment. If manufacturers believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact me at 973-926-6982 or via email at dzehner@barnabashealth.org and/or Robert Pellechio at 973-322-4367, or rpellechio@bamabashealth.org

Sincerely,



Douglas Zehner, Chief Financial Officer